<DOC>
	<DOCNO>NCT01131806</DOCNO>
	<brief_summary>Chronic obstructive pulmonary disease characterize inflammatory airway fully reversible airflow limitation.Combination treatment inhale corticosteroid ( ICS ) long-acting β2 agonist ( LABA ) attain improved control symptom lung function , superior associate either drug alone . However , treatment efficacy high medium dose inhale corticosteroid combination LABA still unknown . The aim current study investigate treatment efficacy high medium dose fluticasone combination salmeterol COPD patient .</brief_summary>
	<brief_title>Comparing Treatment Efficacy With HD/MD Flu Plus Sal Chronic Obstructive Pulmonary Disease ( COPD ) Patients</brief_title>
	<detailed_description>Chronic obstructive pulmonary disease ( COPD ) major cause morbidity use health care resource worldwide . It characterize chronic progressive symptom , airflow obstruction , impair health status , bad frequent , acute episode symptom exacerbation . Treatment COPD focus minimize risk factor , improve symptom , prevent exacerbation . Pulmonary inflammation key factor COPD . Inhaled long-acting β2 agonist ( LABA ) improve airflow obstruction , control symptom , health status patient COPD 3 4 month . Inhaled corticosteroid ( ICS ) currently popular anti-inflammatory medication use symptomatic patient COPD . Previous large scale randomize control study discover long-term use ICS n't modify annual decline lung function COPD patient , may reduce frequency exacerbation , especially combine LABA . Combination treatment ICS LABA widely use patient COPD attain improve control symptom lung function , great risk side-effects treatment either component alone . Combined ICS/LABA result well treatment effect superior associate either drug alone . However , treatment efficacy high medium dose inhale corticosteroid combination LABA still unknown . The aim current study investigate treatment efficacy high medium dose fluticasone combination salmeterol COPD patient .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male female outpatient age ≧ 40 year . Current exsmoker , smoke history ≧ 10 pack year COPD ( FEV1/FVC &lt; 70 % ) patient postbronchodilator FEV1 ≦ 70 % predict value , without bronchial reversibility ( ≦10 % increase post bronchodilator ) . Diagnosis suspicion sleep apnea Concurrent rhinitis , eczema , asthma Clinically overt bronchiectasis , lung cancer , active tuberculosis , know specific pulmonary disease A chest Xray indicate diagnosis COPD might interfere study . Major disease abnormality uncontrolled therapy . Alcohol medication abuse . Patients low respiratory tract infection receive systemic steroid 4 week prior commencement study . Unable unwilling comply protocol specify procedure .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>lung function change FEV1 FVC</keyword>
	<keyword>acute exacerbation</keyword>
	<keyword>life quality questionnaire</keyword>
</DOC>